THE DELIVERABILITY YOU WANT.
THE OUTCOMES YOU EXPECT.
Portico™ with FlexNav™ TAVI System's exceptional design was purposefully built to give you complete, independent control of valve delivery.
- Achieve excellent outcomes without compromising delivery technique1
- Experience a calm, controlled valve deployment, due to continuous hemodynamic stability2
- Treat every case, even the most tortuous anatomies
- Allow for future treatment options by preserving access to coronaries
- Achieve a low profile with integrated sheath
*14 F equivalent integrated sheath diameter for patients requiring 23 mm or 25 mm valve.
A PARTNERSHIP IN EXCELLENCE
- We owe it to our communities to discover novel treatments and continuously improve our current technologies to address unmet—or undertreated—needs with improved benefit-to-risk profiles over current standard of care
A sustainable future starts with health
- We're designing access and affordability into our products to reach one in three people every year by 2030
MAT-2106521 v4.0 | Item approved for U.S. use only.
- Makkar RR, Cheng W, Waksman R, et al. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. Lancet. 2020;396:669-683.
- Agnifili M, Brambilla N, Testa L, et al. Use of the SoloPath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.
- Portico IFU.
- Möllmann H, Linke A, Holzhey DM, et al. Implantation and 30-day follow-up on all 4 valve sizes within the Portico transcatheter aortic bioprosthetic family. J Am Coll Cardiol Intv. 2017;10:1538-1547.
- Supplement to Cardiac Interventions Today Europe. vol 4(1) 2020.
- Fontana GP, Bedogni F, Groh M, et al. Safety profile of an intra-annular self-expanding transcatheter aortic valve and next-generation low-profile delivery system. J Am Coll Cardiol Intv. 2020;13:2467-2478.
AORTIC VALVE IMPLANTATION SYSTEM
The Portico™ Transcatheter Aortic Valve Implantation System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).
The valve is contraindicated for patients with inability to tolerate antiplatelet/anticoagulant therapy or nitinol alloy (nickel and titanium), or who have active infections, including endocarditis.
Carefully read all warnings, precautions, and instructions for use for all components of the system before use. Failure to read and follow all instructions or failure to observe all stated warnings could cause serious injury or death to the patient.
- Perform Portico™ valve implantation in a facility where emergency aortic valve surgery is available.
- Verify that the patient’s anatomy is consistent with the specifications set forth in the anatomical specifications tables 2 and 3 (found in IFU).
- For single use only. Do not reuse, reprocess, or resterilize the valve, delivery system, or the loading system. Reuse, reprocessing, and/or resterilization creates a risk of contamination of the devices and/or device failure, which could cause patient injury, illness or death.
- Do not manipulate or handle the valve with sharp or pointed objects.
- Rinse the valve as directed before loading the valve onto the delivery system.
- Do not use the valve, the delivery system, or the loading system if the “USE BY” date has elapsed.
- Exercise care to prevent kinking of the delivery system when removing it from the packaging.
- This device contains nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.
- Accelerated deterioration of the valve due to calcific degeneration may occur in children, adolescents, young adults, or patients with altered calcium metabolism.
- The safety, effectiveness, and durability of a Portico™ valve implanted within a surgical or transcatheter bioprosthesis have not been demonstrated.
- Long-term durability has not been established for the Portico valve. Regular medical follow-up is advised to evaluate valve performance.
- For transaortic access, ensure the access site and trajectory are free of internal patent right internal mammary artery (RIMA) or pre-existing patent RIMA graft.
- For subclavian/axillary access, use caution in patients with mammary artery grafts.
- Balloon aortic valvuloplasty (BAV) of the native aortic valve is recommended prior to delivery system insertion. The balloon size chosen should be appropriate, not exceeding the minimum diameter of the native aortic annulus as assessed by CT imaging to minimize risk of annular rupture and not undersized to minimize risk of stent under-expansion which could lead to paravalvular leak (PVL) or device migration.
- Do not use the valve if the shipping temperature indicator on the product package has turned red, or if the valve has been improperly stored in temperature conditions outside of the 5°C–25°C (41°F–77°F) range.
- Do not use the valve if the tamper-evident container seal is damaged, broken, or missing, or if fluid is leaking from the packaging.
- Do not advance the delivery system without the guidewire extending from the tip.
- Do not use the valve without thoroughly rinsing as directed.
- Do not use the delivery system without thoroughly flushing as described in the "Directions for Use" section.
- The safety and effectiveness of the Portico™ valve and FlexNav™ delivery system have not been evaluated in the following patient populations:
- Congenital unicuspid or bicuspid valve, or any leaflet configuration other than tricuspid
- Severe ventricular dysfunction with left ventricular ejection fraction <20%
- Non-calcific aortic annulus
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Patients at low or intermediate surgical risk
- Patients who are pregnant or breastfeeding
- Pediatric patients (less than 21 years of age)
- Patients with a pre-existing prosthetic heart valve or prosthetic ring in any position
- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation > 3+)
- Patients with severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the LVOT, severe (greater than 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise
- Blood dyscrasias as defined: leukopenia (WBC<3000 mm³), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count <50,000 cells/mm³)
- Patients with untreated clinically significant coronary artery disease requiring revascularization
- Patients with bulky calcified aortic valve leaflets in close proximity to coronary ostia
- Hypertrophic cardiomyopathy with or without obstruction (HOCM)
- Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis
- Hemodynamic instability requiring inotropic support or mechanical heart assistance
- Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5cm or greater; marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding or ulcerated) or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe “unfolding” and tortuosity of the thoracic aorta
- Patients with known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be adequately premedicated
- Patients with access characteristics that would preclude safe placement of the introducer sheath, when necessary, such as severe obstructive calcification, or severe tortuosity
- To minimize risk of guidewire perforations in the left ventricle, a manufacturer pre-shaped guidewire should be used during the procedure and during valve deployment.
- Do not deploy the valve if excessive resistance to deployment is encountered. If the valve does not deploy easily, re-sheath the valve, remove it from the patient, and use a different valve and delivery system.
- Follow the procedure in “Implanting the Valve” to reposition the valve or to remove the valve from the patient.
- Do not attempt to reposition the valve by advancing it distally unless the valve has been fully re-sheathed within the delivery system.
- Do not re-sheath the valve more than two times prior to final valve release. Additional re-sheath attempts may compromise product performance.
- To minimize likelihood of permanent pacemaker implantation (PPI): a) maintain implant depth of 3mm, and b) limit manipulations across the LVOT.
- In the event that a post-implant balloon dilatation is performed to address paravalvular leak (PVL), valve size, patient anatomy, and implant depth must be considered when selecting the size of the balloon for dilatation. The balloon size chosen should not exceed the mean diameter of the native aortic annulus. Moderate or Severe PVL should be addressed at the time of the TAVI procedure.
- Exercise care when removing the delivery system from the patient.
- Exercise care when crossing the valve with adjunctive devices.
- Once the valve is fully deployed, repositioning and retrieval of the valve is not possible. Attempted retrieval (e.g., use of a guidewire, snare, or forceps) may cause aortic root, coronary artery, and/or myocardial damage.
- Valve recipients should be maintained on antiplatelet and/or anticoagulant therapy post procedure, per institutional standards and established guidelines, except when contraindicated, using individualized treatment as determined by their physician.
- Post-implant monitoring and/or possible electrophysiology evaluation may be considered in patients with transient high degree or complete AV block or other conduction disturbances during or following implantation of the valve. This may include continuous ECG monitoring after hospital discharge.
POTENTIAL ADVERSE EVENTS
Adverse events potentially associated with the use of transcatheter bioprosthetic heart valves include but are not limited to:
- access site complications (e.g., pain, bleeding, infection, hematoma, pseudoaneurysm, etc.)
- acute coronary obstruction
- acute myocardial infarction
- allergic reaction to antiplatelet agents, contrast medium, or valve components
- aortic rupture
- ascending aorta trauma
- atrio-ventricular node block
- cardiac arrhythmias
- conduction system injury
- conversion to open surgical procedure
- emergent balloon valvuloplasty
- emergent percutaneous coronary intervention (PCI)
- emergent surgery (i.e., coronary artery bypass, heart valve replacement)
- heart failure
- hemodynamic compromise
- hemolytic anemia
- hypotension or hypertension
- myocardial ischemia
- mitral valve insufficiency
- multi-organ failure
- non-structural dysfunction (i.e., entrapment by pannus, paravalvular leak, inappropriate sizing or positioning)
- pericardial effusion
- perforation of the myocardium, ventricle, or a blood vessel
- permanent disability
- permanent pacemaker
- renal insufficiency or renal failure
- respiratory failure
- structural deterioration (i.e., calcification, leaflet tear)
- valve embolization or migration
- vessel dissection or spasm